The detection of bone resorption marker CTXI
CTXI is type I collagen cross-linking carboxyterminal telopeptide, type I collagen consists of three peptide chains, two of them are α(I) chains, the rest is α(Ⅱ) chain, three uncoiling short peptides exist in the carboxyl terminal of mature type I collagen. CTXI is a telopeptide which is disaggregated from the terminal of type I collagen. Due to the collagen with unique triplex super helical structure, its property is very stable, it cannot be resolved by the general processing temperature and short time heating, it is hard to be digestive absorption and not easy for the body to make full use of.
Type I collagen mainly distributes in the skin, bone, cornea, muscle tendon and tumour, as the indicator of type I collagen degradation, CTXI passes into blood in the form of complete immunogenicity protein, and no further decomposition, so CTXI can be used as bone resorption marker, mainly used for monitoring anti-bone resorption treatment of postmenopausal women and osteopenia individual, evaluating bone metabolic disease (such as hyperparathyroidism, Paget's disease, osteodystrophy). Under the conditions of local osteolysis increase, such as multiple myeloma, bone lytic metastasis, rheumatoid arthritis and fixation, the CTXI increased in the serum can be observed, besides, CTXI has certain value for early diagnosing of bone metastasis of breast cancer.
Because of the low expression of this telopeptide (its concentration is 142.6~1638.9pg/ml in human serum samples, 0~545.8pg/ml in mouse serum samples), it is hard for studying and only a few products of CTXI in market. For meeting the researchers’ needs of the study on CTXI, Cloud-Clone corp has carried on the pointed development to the telopeptide, antibodies and detection kits of CTXI. The specificity of telopeptide (SPA665Hu01, CPA665Hu21, CPA665Hu11, CPA665Hu31), monoclonal antibody (MAA665Hu21) and polyclonal antibodies (PAA665Hu01, LAA665Hu91 and LAA665Hu71) can be supported by experiment data. The content of CTXI in human serum, plasma and other biological fluids can be quantitative determined by detection kits (CEA665Hu), Cloud-Clone corp has also developed the mouse (CEA665Mu) and rat (CEA665Ra) detection kit of CTXI for meeting different researchers’ needs.
At present, the related products of CTXI which are developed by Cloud-Clone corp are high quality, good repeatability and high sensitivity. Regarding to the products of CTXI, we get many reference publications, and the table below briefly list the reference publications of CEA665Hu.
Table1. Reference publications of CEA665Hu detection kit developed by Cloud-Clone corp.
Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial.
Read more(Trials: 1745-6215)
The Journal of Clinical Endocrinology & Metabolism
A Mediterranean Diet Enriched with Olive Oil Is Associated with Higher Serum Total Osteocalcin Levels in Elderly Men at High Cardiovascular Risk。
Read more(PubMed: PMC3462931)
Oxytocin Reverses Ovariectomy-Induced Osteopenia and Body Fat Gain
Read more(Endocrine: Source)
The American Journal of Cardiology
Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease
Bone resorption correlates with the frequency of CD5+ B cells in the blood of patients with rheumatoid arthritis
The presence of FCGR2B promoter or transmembrane region variant alleles leads to reduced serum IL-6 levels in rheumatoid arthritis
Scandinavian Journal of Clinical and Laboratory Investigation
Osteocartilaginous metabolic markers change over a 3-week stage race in pro-cyclists
Read more(PubMed: 26174975)
Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients
Read more(PubMed: 26372384)
the journal of rheumatology
Biomarkers in Remission According to Different Criteria in Patients with RheumatoidArthritis
Read more(PubMed: 26472417)
For more related products, please visit: www.cloud-clone.us.